Prothena Corporation plc (NASDAQ:PRTA) Ratings Summary on May 17, 2018

May 17, 2018 - By Kenneth Sanchez

Prothena Corporation plc (NASDAQ:PRTA) Corporate Logo
Big Money Sentiment decreased to 1.18 in Q4 2017. It has change of 0.47, from 2017Q3’s 1.65. The ratio dived due to Prothena Corporation plc positioning: 29 sold and 32 reduced. 28 funds acquired stakes and 44 increased stakes. Investors holded 31.24 million in 2017Q3 but now own 31.32 million shares or 0.27% more.
Eventide Asset Mngmt Lc reported 120,000 shs. 24,730 are held by Sabby Management Limited. Clearbridge Ltd Liability Corporation invested in 24 shs or 0% of the stock. Moreover, California Pub Employees Retirement Sys has 0% invested in Prothena Corporation plc (NASDAQ:PRTA) for 63,000 shs. Ls Investment Advsr invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Prelude Mgmt Limited Company holds 0% of its capital in Prothena Corporation plc (NASDAQ:PRTA) for 98 shs. Hood River Cap Management Ltd Liability Co holds 213,119 shs. Jefferies Group Ltd Liability Corp holds 0% or 7,802 shs in its capital. 205,000 are owned by Sphera Funds Management. Axa has invested 0.02% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Tower Research Capital Lc (Trc) invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Moreover, Fisher Asset Management Ltd Liability has 0% invested in Prothena Corporation plc (NASDAQ:PRTA) for 27,485 shs. Hudson Bay Cap Management L P owns 50,000 shs for 0.04% of their capital. Oak Ridge Ltd has 0.32% invested in Prothena Corporation plc (NASDAQ:PRTA). Jennison Assocs holds 416,031 shs.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

In total 10 analysts cover Prothena Corp PLC (NASDAQ:PRTA). “Buy” rating has 3, “Sell” are 0, while 7 are “Hold”. (NASDAQ:PRTA) has 30% bullish analysts. 16 are the (NASDAQ:PRTA)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by Cantor Fitzgerald on Tuesday, April 24. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 20. On Monday, April 23 the company was downgraded by Jefferies. The stock rating was maintained by Oppenheimer with “Buy” on Wednesday, March 21. On Monday, December 4 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Buy” rating by Oppenheimer. On Tuesday, April 24 Deutsche Bank maintained Prothena Corporation plc (NASDAQ:PRTA) with “Buy” rating. On Wednesday, December 20 the firm has “Buy” rating given by Cantor Fitzgerald. On Thursday, February 15 the firm has “Buy” rating given by Cantor Fitzgerald. On Thursday, April 5 the firm earned “Overweight” rating by Barclays Capital. On Monday, April 23 Oppenheimer downgraded the shares of PRTA in report to “Hold” rating. Listed here are Prothena Corporation plc (NASDAQ:PRTA) PTs and latest ratings.

24/04/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $87 New Target: $19 Maintain
24/04/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $16 Maintain
24/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $77 Downgrade
24/04/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $14 Maintain
23/04/2018 Broker: Oppenheimer Rating: Hold Downgrade
23/04/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
23/04/2018 Broker: Barclays Capital Rating: Hold Downgrade
23/04/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade
23/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $76 New Target: $12 Downgrade
05/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $50 Maintain

PRTA touched $16.31 during the last trading session after $0.12 change.Currently Prothena Corporation plc is downtrending after 31.00% change in last May 17, 2017. PRTA has also 378,815 shares volume. PRTA underperformed the S&P500 by 42.55%.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.The firm is worth $649.50 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development.Currently it has negative earnings. The firm has a license, development, and commercialization agreement with F.

For more Prothena Corporation plc (NASDAQ:PRTA) news brought out recently go to: Nasdaq.com, Seekingalpha.com, Prnewswire.com, Globenewswire.com or Digitaljournal.com. The titles are as follows: “Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update” brought out on May 08, 2018, “Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target” on April 25, 2018, “PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 …” with a publish date: May 16, 2018, “Prothena to Report First Quarter 2018 Financial Results on May 8” and the last “NASDAQ:PRTA Shareholder Notice: Investigation over Possible Violations of Securities Laws by Prothena Corporation …” with publication date: May 08, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.